MX2011000455A - Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos. - Google Patents

Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.

Info

Publication number
MX2011000455A
MX2011000455A MX2011000455A MX2011000455A MX2011000455A MX 2011000455 A MX2011000455 A MX 2011000455A MX 2011000455 A MX2011000455 A MX 2011000455A MX 2011000455 A MX2011000455 A MX 2011000455A MX 2011000455 A MX2011000455 A MX 2011000455A
Authority
MX
Mexico
Prior art keywords
mab
gal
fgfr2
humanized
human
Prior art date
Application number
MX2011000455A
Other languages
English (en)
Spanish (es)
Inventor
Kyung Jin Kim
Hangil Park
Maximiliano Vasquez
Wei-Meng Zhao
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of MX2011000455A publication Critical patent/MX2011000455A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2011000455A 2008-11-07 2009-11-06 Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos. MX2011000455A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11268608P 2008-11-07 2008-11-07
US16487009P 2009-03-30 2009-03-30
PCT/US2009/063647 WO2010054265A2 (en) 2008-11-07 2009-11-06 Monoclonal antibodies to fibroblast growth factor receptor 2

Publications (1)

Publication Number Publication Date
MX2011000455A true MX2011000455A (es) 2011-02-25

Family

ID=42153600

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011000455A MX2011000455A (es) 2008-11-07 2009-11-06 Anticuerpos monoclonales especificos al receptor 2 del factor de crecimiento de fibroblastos.

Country Status (20)

Country Link
US (8) US8101723B2 (enExample)
EP (4) EP2365828B1 (enExample)
JP (8) JP5627591B2 (enExample)
KR (1) KR101699432B1 (enExample)
CN (1) CN102131524B (enExample)
AU (1) AU2009313357B2 (enExample)
BR (1) BRPI0917315B8 (enExample)
CA (1) CA2733668C (enExample)
DK (3) DK2842573T3 (enExample)
ES (3) ES2523740T3 (enExample)
HR (2) HRP20171640T1 (enExample)
HU (1) HUE035700T2 (enExample)
LT (2) LT2842573T (enExample)
MX (1) MX2011000455A (enExample)
NO (1) NO2842573T3 (enExample)
PL (3) PL2842573T3 (enExample)
PT (3) PT2365828E (enExample)
RU (1) RU2546254C9 (enExample)
SI (2) SI3290052T1 (enExample)
WO (1) WO2010054265A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
KR101699432B1 (ko) 2008-11-07 2017-01-24 갤럭시 바이오테크, 엘엘씨 섬유아세포성장인자수용체 ２에 대한 모노클로날 항체
US8481688B2 (en) * 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
EP2603521A4 (en) * 2010-08-12 2014-10-01 Attogen Inc ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
RU2014128467A (ru) 2011-12-14 2016-02-10 Сиэтл Дженетикс, Инк. Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
EP2822968B1 (en) 2012-03-08 2018-01-10 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
CN104334724B (zh) * 2012-04-09 2020-09-01 第一三共株式会社 抗-fgfr2抗体
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JP6488236B2 (ja) * 2012-12-21 2019-03-20 ヤンセン バイオテツク，インコーポレーテツド 可溶型線維芽細胞増殖因子受容体の高感度多重イムノアッセイ
CN103145843B (zh) * 2013-02-20 2014-10-29 暨南大学 抗成纤维细胞生长因子受体的单链抗体
HK1213180A1 (zh) 2013-03-06 2016-06-30 豪夫迈‧罗氏有限公司 治疗和预防癌症药物抗性的方法
PL3027651T3 (pl) * 2013-08-01 2019-08-30 Five Prime Therapeutics, Inc. Afukozylowane przeciwciała anty-fgfr2iiib
ES2768618T3 (es) * 2013-10-08 2020-06-23 Daiichi Sankyo Co Ltd Combinación de anticuerpo anti-FGFR2 y otro agente
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CN104231079A (zh) * 2014-09-12 2014-12-24 暨南大学 一种靶向bFGF高亲和力受体结合位点的抗体及其应用
JP6887944B2 (ja) * 2015-04-08 2021-06-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤を含む組成物
EP3287522A4 (en) * 2015-04-20 2019-03-27 Daiichi Sankyo Company, Limited DETECTION OF FGFR2
RU2638457C2 (ru) * 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
KR20250034528A (ko) 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
RS67296B1 (sr) 2017-05-16 2025-11-28 Five Prime Therapeutics Inc Anti-fgfr2 antitela u kombinaciji sa sredstvima za hemoterapiju u lečenju karcinoma
EP3630818A1 (en) 2017-06-02 2020-04-08 Ablynx NV Aggrecan binding immunoglobulins
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
MX2020004140A (es) 2017-10-24 2020-08-13 Magenta Therapeutics Inc Composiciones y metodos para la eliminacion de celulas cd117+.
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
US20220010020A1 (en) 2018-10-05 2022-01-13 Five Prime Therapeutics, Inc. Anti-FGFR2 Antibody Formulations
MX2022007960A (es) * 2019-12-24 2022-07-12 Dizal Jiangsu Pharmaceutical Co Ltd Nuevos anticuerpos anti-fgfr2b.
AR120886A1 (es) * 2019-12-24 2022-03-30 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
JP2023528454A (ja) * 2020-06-03 2023-07-04 ザ・ブロード・インスティテュート・インコーポレイテッド 線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法
WO2022087243A1 (en) 2020-10-22 2022-04-28 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
US20240101683A1 (en) * 2020-12-29 2024-03-28 Shenzhen Forward Pharmaceuticals Co., Limited Anti-FGFR2 Antibody and Use Thereof
EP4414387A4 (en) * 2021-10-08 2025-10-29 Shenzhen Forward Pharmaceuticals Co Ltd ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
EP4594356A1 (en) * 2022-09-30 2025-08-06 3H Pharmaceuticals Co., Ltd. Anti-fgfr2b antibodies and uses thereof
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
CN118994393A (zh) * 2023-05-19 2024-11-22 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
CN119855835A (zh) * 2023-06-13 2025-04-18 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
TW202527998A (zh) * 2023-12-18 2025-07-16 大陸商山東先聲生物製藥有限公司 抗FGFR2b抗體-藥物綴合物及其應用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE179862T1 (de) 1989-07-06 1999-05-15 Univ California Rezeptoren für fibroblasten-wachstumsfaktoren
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
WO1995010540A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en) 1996-06-18 1998-01-07 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
US6342221B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody conjugate compositions for selectively inhibiting VEGF
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
US20020115603A1 (en) 2000-06-22 2002-08-22 Chiron Corporation Methods and compositions for the treatment of peripheral artery disease
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
ATE440869T1 (de) 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
US7531304B2 (en) 2002-01-31 2009-05-12 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Method for screening FGFR-4 agonists
KR100493460B1 (ko) * 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
MEP31408A (en) 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
CA2550245A1 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7872016B2 (en) 2004-05-25 2011-01-18 Yale University Method for treating skeletal disorders resulting from FGFR malfunction
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2651755A1 (en) * 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
JP4560582B2 (ja) 2006-06-02 2010-10-13 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
EP2433966A1 (en) * 2006-11-03 2012-03-28 U3 Pharma GmbH FGFR4 antibodies
CN101903534B (zh) * 2007-03-23 2014-07-30 翻译基因组学研究院 诊断、分类和治疗子宫内膜癌和初癌的方法
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US20110059091A1 (en) 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
KR101699432B1 (ko) 2008-11-07 2017-01-24 갤럭시 바이오테크, 엘엘씨 섬유아세포성장인자수용체 ２에 대한 모노클로날 항체
WO2011025814A1 (en) 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury

Also Published As

Publication number Publication date
EP3290052A1 (en) 2018-03-07
HK1249053A1 (en) 2018-10-26
ES2770134T3 (es) 2020-06-30
KR101699432B1 (ko) 2017-01-24
ES2646168T3 (es) 2017-12-12
US10689448B2 (en) 2020-06-23
US10138301B2 (en) 2018-11-27
US8603987B2 (en) 2013-12-10
RU2546254C9 (ru) 2015-07-10
JP2014240385A (ja) 2014-12-25
CA2733668C (en) 2022-08-30
US20190153105A1 (en) 2019-05-23
CA3166399A1 (en) 2010-05-14
EP2842573B1 (en) 2017-09-27
US20160362496A1 (en) 2016-12-15
HK1207974A1 (en) 2016-02-19
WO2010054265A2 (en) 2010-05-14
AU2009313357A1 (en) 2010-05-14
JP2023116746A (ja) 2023-08-22
PT2842573T (pt) 2017-12-04
RU2011141890A (ru) 2013-04-27
US20140193899A1 (en) 2014-07-10
JP2019052165A (ja) 2019-04-04
BRPI0917315B1 (pt) 2020-12-08
JP6661734B2 (ja) 2020-03-11
EP2365828A2 (en) 2011-09-21
US20180094063A1 (en) 2018-04-05
HRP20171640T1 (hr) 2018-01-12
NO2842573T3 (enExample) 2018-02-24
JP6960485B2 (ja) 2021-11-05
LT2842573T (lt) 2017-12-11
DK3290052T3 (da) 2020-02-03
US9382324B2 (en) 2016-07-05
EP2842573A1 (en) 2015-03-04
WO2010054265A3 (en) 2010-09-16
JP6342223B2 (ja) 2018-06-13
PL3290052T3 (pl) 2020-06-29
DK2842573T3 (en) 2017-10-30
KR20110081141A (ko) 2011-07-13
BRPI0917315B8 (pt) 2021-05-25
PT3290052T (pt) 2020-02-06
US20120134994A1 (en) 2012-05-31
EP2365828B1 (en) 2014-10-15
SI2842573T1 (en) 2018-01-31
JP2012508184A (ja) 2012-04-05
EP2365828A4 (en) 2012-06-06
JP7301106B2 (ja) 2023-06-30
JP2020096615A (ja) 2020-06-25
AU2009313357B2 (en) 2015-06-11
ES2523740T3 (es) 2014-12-01
CA2733668A1 (en) 2010-05-14
JP6445496B2 (ja) 2018-12-26
JP2022008996A (ja) 2022-01-14
DK2365828T3 (en) 2014-12-08
JP2017019807A (ja) 2017-01-26
CN102131524B (zh) 2014-05-14
PL2365828T3 (pl) 2015-04-30
JP5627591B2 (ja) 2014-11-19
US9834609B2 (en) 2017-12-05
JP2025032085A (ja) 2025-03-11
RU2546254C2 (ru) 2015-04-10
US20200347141A1 (en) 2020-11-05
US20100196364A1 (en) 2010-08-05
HRP20200090T1 (hr) 2020-04-03
EP3783024A1 (en) 2021-02-24
PL2842573T3 (pl) 2018-04-30
LT3290052T (lt) 2020-02-25
CN102131524A (zh) 2011-07-20
US8101723B2 (en) 2012-01-24
HK1160012A1 (en) 2012-08-10
PT2365828E (pt) 2014-12-12
US20230242650A1 (en) 2023-08-03
HUE035700T2 (en) 2018-05-28
EP3290052B1 (en) 2019-12-25
BRPI0917315A2 (pt) 2015-11-17
SI3290052T1 (sl) 2020-07-31

Similar Documents

Publication Publication Date Title
JP6960485B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
KR20110011710A (ko) 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
HK1249053B (en) Monoclonal antibodies to fibroblast growth factor receptor 2
HK1207974B (en) Monoclonal antibodies to fibroblast growth factor receptor 2

Legal Events

Date Code Title Description
FG Grant or registration